The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 15, 2021

Filed:

Jun. 09, 2015
Applicants:

Biomed Valley Discoveries, Inc., Kansas City, MO (US);

The United States of America, As Represented BY the Secretary, Department of Health and Human Services, Bethesda, MD (US);

Inventors:

Saurabh Saha, Wellesley Hills, MA (US);

Xiaoyan M. Zhang, Lexington, MA (US);

Dimiter Dimitrov, Frederick, MD (US);

Zhongyu Zhu, Frederick, MD (US);

Brad St. Croix, Frederick, MD (US);

Enrique Zudaire, Germantown, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); C07K 16/22 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61K 31/192 (2006.01); A61K 31/4745 (2006.01); C07K 16/30 (2006.01);
U.S. Cl.
CPC ...
C07K 16/22 (2013.01); A61K 31/192 (2013.01); A61K 31/4745 (2013.01); A61K 39/395 (2013.01); A61K 39/39558 (2013.01); C07K 16/28 (2013.01); C07K 16/30 (2013.01); C07K 16/303 (2013.01); C07K 16/3015 (2013.01); C07K 16/3023 (2013.01); C07K 16/3038 (2013.01); C07K 16/3053 (2013.01); C07K 16/3069 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/72 (2013.01); C07K 2317/732 (2013.01); C07K 2317/92 (2013.01);
Abstract

The present invention provides, inter alia, methods for treating or ameliorating the effects of a disease, such as cancer, in a subject. The methods include: administering to a subject in need thereof (a) a therapeutically effective amount of a monoclonal antibody or antigen binding fragment of the present invention, and (b) a therapeutically effective amount of a combination therapy including bevacizumab and at least one additional therapeutic agent; or a therapeutically effective amount of at least one additional therapeutic agent selected from the group consisting of a COX-2 inhibitor (COXIB), a non-steroidal anti-inflammatory drug (NSAID), a prostaglandin E2 (PGE2) synthase inhibitor, and combinations thereof. Compositions, including pharmaceutical compositions, and kits for treating diseases, such as cancer, are also provided herein.


Find Patent Forward Citations

Loading…